Discovery of a potent, non-peptide bradykinin B1 receptor antagonist

Journal of the American Chemical Society

Volumn 125, Issue 25, 2003, Pages 7516-7517

  Su, Dai Shi ^a   Markowitz, M Kristine ^a   DiPardo, Robert M ^a   Murphy, Kathy L ^a   Harrell, C Meacham ^a   O'Malley, Stacy S ^a   Ransom, Richard W ^a   Chang, Raymond S L ^a   Ha, Sookhee ^a   Hess, Fred J ^a   Pettibone, Douglas J ^a   Mason, Glenn S ^b   Boyce, Susan ^b   Freidinger, Roger M ^a   Bock, Mark G ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTACOID; BRADYKININ B1 RECEPTOR ANTAGONIST; BRADYKININ B2 RECEPTOR; DIHYDROQUINOXALINONE; QUINOXALINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINOCICEPTION; ARTICLE; BINDING AFFINITY; BINDING SITE; DRUG POTENCY; HUMAN; INFLAMMATION; NONHUMAN; PAIN; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION;

ANALGESICS; ANIMALS; BINDING SITES; DOGS; HUMANS; KINETICS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; PAIN MEASUREMENT; QUINOXALINES; RABBITS; RATS; RECEPTOR, BRADYKININ B1; RECEPTORS, BRADYKININ; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0038546886     PISSN: 00027863     EISSN: None     Source Type: Journal    
DOI: 10.1021/ja0353457     Document Type: Article

References (17)

1. For excellent reviews, see: . Couture, R.; Harrisson, M.; Vianna, R. M.; Cloutier, F. Eur. J. Pharmacol. 2001, 429, 161-176.
2. Bock, M. G.; Longmore, J. Curr. Opin. Chem. Biol. 2000, 4, 401-406.
3. Marceau, F. Immunopharmacology 1995, 30, 1-26.
4. Regoli, D.; Barabe, J. Pharmacol. Rev. 1980, 32, 1-46.
5. Rupniak, N. M. J.; Longmore, J.; Hill, R. G. In Molecular Basis of Pain Induction; Wood, J., Ed.; John Wiley Press: 2000; 149-174.
6. Pesquero, J. B.; Araujo, R. C.; Heppenstall, P. A.; Stucky, C. L.; Silva, J. A., Jr.; Walther, T.; Oliveira, S. M.; Pesquero, J. L.; Paiva, A. C. M.; Calixto, J. B.; Lewin, G. R.; Bader, M. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 8140-8145.
7. Ferreira, J.; Campos, M. M.; Araujo, R.; Bader, M.; Pesquero, J. B.; Calixto, J. B. Neuropharmacology 2002, 43, 1188-1197.
8. Palczewski, K., Kumasaka, T.; Hori, T.; Behnke, C. A.; Motoshima, H.; Fox, B. A.; Trong, I. L.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M. Science 2000, 289, 739-745.
9. A manuscript with detailed coordinates of this model is in preparation.
10. See Supporting Information for the synthetic route and preparation of compounds.
11. Fathy, D. B.; Mathis, S. A.; Leeb, T.; Leeb-Lundberg, L. M. F. J. Biol. Chem. 1998, 273, 12210-12218.
12. Bastian, S.; Pruneau, D.; Loillier, B.; Robert, C.; Bonnafous, J.-C.; Paquet, J.-L. J. Biol. Chem. 2000, 275, 6107-6113.
13. Hess, J. F.; Hey, P. J.; Chen, T.-B.; Pettibone, D. J.; Chang, R. S. L. Int. Immunopharmacol. 2002, 2, 1747-1754.
14. Fathy, D. B.; Kyle, D. J.; Leeb-Lundberg, L. M. F. Mol. Pharmacol. 2000, 57, 171-179.
15. 50: 0.18 nM (human), 0.26 nM (rabbit), 16.30 nM (dog), and 163.5 nM (rat). See Supporting Information for assay protocol.
16. Panlabs (MDS Pharma Services, Bothell, WA).
17. 50: 299, μg/kg (low-intensity stimuli). See Supporting Information for results and the assay protocol.